Bosnia and Herzegovina vs Georgia: Share of S. aureus infections resistant to methicillin
Bosnia and Herzegovina
26.5%
in 2022
Georgia
28.3%
in 2022
Bosnia and Herzegovina rank
23rd
Georgia rank
22nd
Share of S. aureus infections resistant to methicillin over time
- Bosnia and Herzegovina
- Georgia
How they compare
Georgia currently reports 28.3% against 26.5% in Bosnia and Herzegovina, a difference of 1.8%.
That makes Georgia's figure about 1.1 times Bosnia and Herzegovina's.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Bosnia and Herzegovina ahead.
Bosnia and Herzegovina ranks 23rd and Georgia ranks 22nd of 45 countries.
Across the 2 decades both report, Bosnia and Herzegovina averaged higher in 1 and Georgia in 1.
Head to head by decade
| Decade | Bosnia and Herzegovina | Georgia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 17.6% | 9.4% | 8.1% | Bosnia and Herzegovina |
| 2020s | 23.5% | 24.6% | 1.1% | Georgia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of s. aureus infections resistant to methicillin, Bosnia and Herzegovina or Georgia?
- Georgia, at 28.3% against 26.5% in Bosnia and Herzegovina as of 2022.
- What is the difference in share of s. aureus infections resistant to methicillin between Bosnia and Herzegovina and Georgia?
- 1.8%, with Georgia ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Georgia?
- 6 years are reported by both, from 2017 to 2022.
- How do Bosnia and Herzegovina and Georgia rank globally for share of s. aureus infections resistant to methicillin?
- Bosnia and Herzegovina ranks 23rd and Georgia ranks 22nd of 45 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of S. aureus infections resistant to methicillin. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%).